Richard K Sterling1, Abdus S Wahed2, Wendy C King2, David E Kleiner3, Mandana Khalili4, Mark Sulkowski5, Raymond T Chung6, Mamta K Jain7, Mauricio Lisker-Melman8, David K Wong9, Marc G Ghany3. 1. Virginia Commonwealth University, Richmond, VA, USA. 2. University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, USA. 3. National Institutes of Health, Bethesda, MD, USA. 4. University of California at San Francisco, San Francisco, CA, USA. 5. The Johns Hopkins University, Baltimore, MD, USA. 6. Massachusetts General Hospital, Boston, MA, USA. 7. University of Texas Southwestern, Dallas, TX, USA. 8. Washington University School of Medicine, St. Louis, MO, USA. 9. University Health Network, Toronto, ON, Canada.
Abstract
BACKGROUND: Because most HBV/HIV co-infected patients on combination antiretroviral therapy (cART) have suppressed HBV DNA and normal liver enzymes, the histologic spectrum of liver disease in HBV/HIV coinfection is poorly defined. To address this gap in knowledge, we conducted a prospective study to comprehensively characterize liver disease severity assessed by liver biopsy in a well-defined cohort of HBV/HIV patients in North America receiving cART. METHODS: Adult HIV/HBsAg positive patients on stable cART were recruited. Demographic, clinical, serological, and virological data were collected. Liver histology was assessed by a central pathology committee. The association of demographic, clinical, serologic, and virologic characteristics with liver histology was assessed using logistic regression. RESULTS: In this cross-sectional analysis, the mean age of the cohort (N = 139) was 49 years; 92% were male, 51% were non-Hispanic black, 7% had at-risk alcohol use with a median duration of infections of 14 years. The median ALT was 28 IU/L and CD4 count was 568 cells/mm. Almost all (99%) were on cART. Three-fourths (75%) had undetectable HIV RNA (<20 copies/mL). HBeAg was positive in 62%, HBV DNA was below the limit of quantification (<20 IU/mL) in 57% and <1000 IU/ mL in 80%; 7% had incomplete viral suppression (HBV DNA ≥1000 IU/mL and HIV RNA <20 copies/mL). Liver histology (available in n = 114) showed significant periportal, lobular, and portal inflammation (scores ≥2) in 14%, 31%, and 22% respectively. Over a third (37%) had significant fibrosis (Ishak stage ≥2); 24% had advanced fibrosis (Ishak stage ≥3). Higher ALT (adjusted OR 1.19 per 10 IU/L; 95% CI [1.01, 1.41]; p = 0.03) and lower platelet count (adjusted OR 0.81 per 20,000 mm; 95% CI [0.67-0.97]; p = 0.02) but not HBV DNA were independently associated with advanced fibrosis. CONCLUSIONS: In this cohort of patients with HBV/HIV coinfection receiving long-term cART with viral suppression, we observed significant fibrosis in more than one-third of patients.
BACKGROUND: Because most HBV/HIV co-infectedpatients on combination antiretroviral therapy (cART) have suppressed HBV DNA and normal liver enzymes, the histologic spectrum of liver disease in HBV/HIV coinfection is poorly defined. To address this gap in knowledge, we conducted a prospective study to comprehensively characterize liver disease severity assessed by liver biopsy in a well-defined cohort of HBV/HIVpatients in North America receiving cART. METHODS: Adult HIV/HBsAg positive patients on stable cART were recruited. Demographic, clinical, serological, and virological data were collected. Liver histology was assessed by a central pathology committee. The association of demographic, clinical, serologic, and virologic characteristics with liver histology was assessed using logistic regression. RESULTS: In this cross-sectional analysis, the mean age of the cohort (N = 139) was 49 years; 92% were male, 51% were non-Hispanic black, 7% had at-risk alcohol use with a median duration of infections of 14 years. The median ALT was 28 IU/L and CD4 count was 568 cells/mm. Almost all (99%) were on cART. Three-fourths (75%) had undetectable HIV RNA (<20 copies/mL). HBeAg was positive in 62%, HBV DNA was below the limit of quantification (<20 IU/mL) in 57% and <1000 IU/ mL in 80%; 7% had incomplete viral suppression (HBV DNA ≥1000 IU/mL and HIV RNA <20 copies/mL). Liver histology (available in n = 114) showed significant periportal, lobular, and portal inflammation (scores ≥2) in 14%, 31%, and 22% respectively. Over a third (37%) had significant fibrosis (Ishak stage ≥2); 24% had advanced fibrosis (Ishak stage ≥3). Higher ALT (adjusted OR 1.19 per 10 IU/L; 95% CI [1.01, 1.41]; p = 0.03) and lower platelet count (adjusted OR 0.81 per 20,000 mm; 95% CI [0.67-0.97]; p = 0.02) but not HBV DNA were independently associated with advanced fibrosis. CONCLUSIONS: In this cohort of patients with HBV/HIV coinfection receiving long-term cART with viral suppression, we observed significant fibrosis in more than one-third of patients.
Authors: Colette Smith; Caroline A Sabin; Jens D Lundgren; Rodolphe Thiebaut; Rainer Weber; Matthew Law; Antonella d'Arminio Monforte; Ole Kirk; Nina Friis-Moller; Andrew Phillips; Peter Reiss; Wafaa El Sadr; Christian Pradier; Signe W Worm Journal: AIDS Date: 2010-06-19 Impact factor: 4.177
Authors: Maria Buti; Edward Gane; Wai Kay Seto; Henry L Y Chan; Wan-Long Chuang; Tatjana Stepanova; Aric-Josun Hui; Young-Suk Lim; Rajiv Mehta; Harry L A Janssen; Subrat K Acharya; John F Flaherty; Benedetta Massetto; Andrea L Cathcart; Kyungpil Kim; Anuj Gaggar; G Mani Subramanian; John G McHutchison; Calvin Q Pan; Maurizia Brunetto; Namiki Izumi; Patrick Marcellin Journal: Lancet Gastroenterol Hepatol Date: 2016-09-22
Authors: Henry L Y Chan; Scott Fung; Wai Kay Seto; Wan-Long Chuang; Chi-Yi Chen; Hyung Joon Kim; Aric Josun Hui; Harry L A Janssen; Abhijit Chowdhury; Tak Yin Owen Tsang; Rajiv Mehta; Edward Gane; John F Flaherty; Benedetta Massetto; Anuj Gaggar; Kathryn M Kitrinos; Lanjia Lin; G Mani Subramanian; John G McHutchison; Young-Suk Lim; Subrat K Acharya; Kosh Agarwal Journal: Lancet Gastroenterol Hepatol Date: 2016-09-22
Authors: Marc G Ghany; Robert Perrillo; Ruosha Li; Steven H Belle; Harry L A Janssen; Norah A Terrault; Margaret C Shuhart; Daryl T-Y Lau; W Ray Kim; Michael W Fried; Richard K Sterling; Adrian M Di Bisceglie; Steven-Huy B Han; Lilia Milkova Ganova-Raeva; Kyong-Mi Chang; Anna Suk-Fong Lok Journal: Clin Gastroenterol Hepatol Date: 2014-07-08 Impact factor: 11.382
Authors: Richard K Sterling; Wendy C King; Abdus S Wahed; David E Kleiner; Mandana Khalili; Mark Sulkowski; Raymond T Chung; Mamta K Jain; Mauricio Lisker-Melman; David K Wong; Marc G Ghany Journal: Hepatology Date: 2019-08-19 Impact factor: 17.425
Authors: Vincent Lo Re; Craig W Newcomb; Dena M Carbonari; Jason A Roy; Keri N Althoff; Mari M Kitahata; K Rajender Reddy; Joseph K Lim; Michael J Silverberg; Angel M Mayor; Michael A Horberg; Edward R Cachay; Gregory D Kirk; Mark Hull; John Gill; Timothy R Sterling; Jay R Kostman; Marion G Peters; Richard D Moore; Marina B Klein; H Nina Kim Journal: J Acquir Immune Defic Syndr Date: 2019-09-01 Impact factor: 3.731
Authors: Mandana Khalili; Wendy C King; David E Kleiner; Mamta K Jain; Raymond T Chung; Mark Sulkowski; Mauricio Lisker-Melman; David K Wong; Marc Ghany; Arun Sanyal; Richard K Sterling Journal: Clin Infect Dis Date: 2021-11-02 Impact factor: 20.999
Authors: Raymond T Chung; Wendy C King; Marc G Ghany; Mauricio Lisker-Melman; Amanda S Hinerman; Mandana Khalili; Mark Sulkowski; Mamta K Jain; Eun-Young K Choi; Michael A Nalesnik; Atul K Bhan; Gavin Cloherty; David K Wong; Richard K Sterling Journal: Clin Gastroenterol Hepatol Date: 2021-12-29 Impact factor: 13.576
Authors: Berend J van Welzen; Colette Smit; Anders Boyd; Faydra I Lieveld; Tania Mudrikova; Peter Reiss; Annemarie E Brouwer; Andy I M Hoepelman; Joop E Arends Journal: Open Forum Infect Dis Date: 2020-06-25 Impact factor: 3.835
Authors: Richard K Sterling; Wendy C King; Mandana Khalili; David E Kleiner; Amanda S Hinerman; Mark Sulkowski; Raymond T Chung; Mamta K Jain; M Auricio Lisker-Melman; David K Wong; Marc G Ghany Journal: Dig Dis Sci Date: 2021-02-08 Impact factor: 3.487
Authors: Richard K Sterling; Wendy C King; Mandana Khalili; Raymond T Chung; Mark Sulkowski; Mamta K Jain; Mauricio Lisker-Melman; Marc G Ghany; David K Wong; Amanda S Hinerman; Atul K Bhan; Abdus S Wahed; David E Kleiner Journal: Hepatology Date: 2021-08-25 Impact factor: 17.298